Answers are grounded in this paper and cite their sources.
Functional biliary disorders represent a heterogeneous group of conditions in which biliary pain and/or dyspeptic symptoms occur in the setting of impaired gallbladder motility, altered rheological properties of bile, and sphincter incoordination in the absence of structural pathology that could fully explain the clinical manifestations. In current gastroenterological practice, approaches to the verification of these conditions have undergone a substantial transformation towards greater diagnostic rigor. According to the Rome V criteria, the definition of typical biliary pain has been refined, and the diagnostic parameters for functional gallbladder disorders and sphincter of Oddi dysfunction have been revised. The new guidelines place particular emphasis on the exclusion of organic pathology, as well as the minimization of unjustified invasive diagnostic and therapeutic interventions. These provisions are of fundamental importance for determining patient management strategies and for justifying the role of conservative therapeutic approaches, including the use of herbal medicinal products, in patients without tructural changes in the biliary system. Artichoke leaf extract (ALE) – Cynara cardunculus L. (syn. Cynara scolymus L.) – is characterized by a complex phytochemical profile including cynarine, related caffeoylquinic acids, cynaropicrin, flavonoids, and other phenolic compounds. These biologically active substances determine its multifactorial pharmacological action, including choleretic, cholekinetic, antioxidant, and metabolic effects, as well as spasmolytic potential. This article analyzes the pharmacological rationale for the use of an ALE-based medicinal product in functional biliary disorders, biliary sludge, and metabolic dysfunction-associated steatotic liver disease (MASLD), alongside an assessment of the limitations of the existing evidence base. In addition, data from current systematic reviews and meta-analyses published between 2020 and 2025 on the use of ALE are presented, as well as the consensus on MASLD nomenclature (2023), materials from the Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA), and current data on the risk of gallbladder disease during therapy with glucagon-like peptide-1 receptor agonists. Given the provisions of the Rome V criteria, the most appropriate clinical application for ALE is comprehensive conservative therapy in carefully selected patients with typical biliary pain, biliary dyspeptic symptoms, or signs of impaired gallbladder motility, in the absence of gallstones and structural obstruction of the biliary tract.
No takes yet. Share an insight, caveat, or question.
Kaplina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: